WSL
ALXN

Western Standard LLC’s Alexion Pharmaceuticals ALXN Stock Holding History

Western Standard LLC’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-143,982
Closed -$26.5M – 43
2021
Q2 		$26.5M Buy
143,982
+9,047
+7% +$1.55M 15.56% 1
2021
Q1 		$20.6M Buy
+134,935
New +$20.9M 14.71% 1

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Western Standard LLC's ALXN Position: Q3 2021 in Review

Western Standard LLC sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 143,982 shares — an estimated $26.5M sold.

Western Standard LLC first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $26.5M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Western Standard LLC reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Western Standard LLC sold 143,982 Alexion Pharmaceuticals shares in Q3 2021, an estimated $26.5M.
  • Western Standard LLC first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Western Standard LLC's Alexion Pharmaceuticals position peaked at $26.5M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Western Standard LLC's 13F filing for Q3 2021, filed 15 Nov 2021.